The catalyst behind the opioid drugmaker’s surge northward was a story in the New York Post over the weekend stating that the private equity firm KKR& Co. The activist hedgefund Starboard Value has been attempting to get Depomed to entertain buyout offers for awhile now, only to have management balk at the idea.